Algatech

Algatech is a world leader in the research, cultivation and commercialisation of microalgae, one of the earliest life forms and a proven source of crucial nutrients. Based at Kibbutz Ketura in southern Israel, the Company's mission is to unlock the immense health benefits of these vital plants through meticulous R&D and cutting-edge technology. The company currently exports its products to leading brands in more than 35 countries worldwide across the nutrition, cosmetics, food and beverages industries. Since its inception in 1998, Algatech has collated a team of 70 global experts and pioneers in biology, engineering, science, production and technology, all passionate and committed to breaking new ground in the development and productisation of microalgae. From its state-of-the-art eco-friendly facility in Israel's Arava Desert, the team has developed techniques to cultivate algae in over 600km of greenhouse-like glass tubes, a process operated entirely on renewable energy. The location's harsh and stable climate, high year-round light intensity and clean, unpolluted air are critical to successful and sustainable algae production. The process is designed to mimic nature's processes using solar energy and recycled wastewater, with the only waste produced being oxygen. The near million different species of algae have the potential to be hugely valuable sources of ingredients, including proteins, omegas, vitamins, carotenoids and polysaccharides, but only a handful are currently commercialised. Leveraging its cutting edge eco-friendly technologies and state-of-the-art scientific methods, the Company has become the leading manufacturer and supplier of astaxanthin, one of the world's most powerful antioxidants sourced from the microalgae Haematococcus pluvialis, which it markets as AstaPure® Astaxanthin and sells as an active bulk ingredient to customers worldwide. Algatech also recently started to market FucoVital™, from the microalgae Phaeodactylum, a proprietary composition for targeting liver health and metabolism syndrome. Algatech has an ambitious product pipeline that will add significant value to the wellbeing of humans and animals around the world. Algatech plans to introduce additional novel ingredients in the coming years and bring new ingredients sourced from microalgae to a market currently worth 2 billion USD.